TriSalus Life Sciences Q3 revenue misses estimates
TLSI•TriSalus Life Sciences' third-quarter revenue rose 11% year over year to $12.88 million, below the $14.02 million consensus estimate. The company narrowed its operating and adjusted EBITDA losses and revised 2026 revenue guidance to $46 million-$48 million.
1. Quarterly results
Third-quarter revenue increased 11% year over year to $12.88 million, missing the $14.02 million analyst estimate. The company reported a $0.15 loss per share and gross profit of $11.10 million. Its operating and adjusted EBITDA losses narrowed, helped by improved gross margins and lower research and development costs.
2. Outlook and drivers
TriSalus revised its 2026 revenue guidance to $46 million-$48 million, implying 2%-6% growth over 2025, and expects continued growth in 2027, citing commercial expansion and new product launches. It said higher TriNav system sales drove quarterly revenue growth, while lower cost per TriNav unit improved gross margins. The company said productivity among its expanded commercial team ramped more slowly than expected. CMS finalized expanded reimbursement for PEDD procedures, effective January 2027.
